| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044669857 |
| P356 | DOI | 10.1186/S13058-014-0405-Y |
| P932 | PMC publication ID | 4187249 |
| P698 | PubMed publication ID | 25056500 |
| P5875 | ResearchGate publication ID | 264245534 |
| P2093 | author name string | Binghe Xu | |
| Zhenzhou Shen | |||
| Michelle DeSilvio | |||
| Junlan Yang | |||
| Mark Russo | |||
| Zhongzhen Guan | |||
| Catherine Ellis | |||
| Zefei Jiang | |||
| Meggan Leigh | |||
| Zhongshen Tong | |||
| P2860 | cites work | Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. | Q54443173 |
| Erratum: Integrated genomic analyses of ovarian carcinoma | Q59096333 | ||
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | Q27824826 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
| Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. | Q33579653 | ||
| PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer | Q33933172 | ||
| PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib | Q33933626 | ||
| Deconstructing the molecular portraits of breast cancer | Q34154147 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer | Q35584560 | ||
| PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups | Q36393206 | ||
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
| Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial | Q37065849 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. | Q37424096 | ||
| Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. | Q37454306 | ||
| Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. | Q37877173 | ||
| PIK3CA mutation associates with improved outcome in breast cancer. | Q38420422 | ||
| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib | Q39700483 | ||
| Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells | Q40345016 | ||
| Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors | Q42486625 | ||
| Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. | Q43579660 | ||
| PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. | Q45903277 | ||
| Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
| Genetic alterations and oncogenic pathways associated with breast cancer subtypes | Q46047984 | ||
| Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy | Q46796554 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 405 | |
| P577 | publication date | 2014-07-24 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa | |
| P478 | volume | 16 |
| Q37221249 | Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status |
| Q92520871 | BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy |
| Q52595390 | Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. |
| Q54259231 | HSP60 overexpression increases the protein levels of the p110α subunit of phosphoinositide 3-kinase and c-Myc. |
| Q90729183 | Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q28081992 | PI3K mutations in breast cancer: prognostic and therapeutic implications |
| Q64106572 | PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial |
| Q57494109 | Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer |
| Q52655751 | Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. |
| Q90226704 | Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives |
| Q36064908 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer |
| Q35801713 | Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study |
| Q39441303 | Targeting PI3K Signaling in Combination Cancer Therapy. |
| Q41645967 | The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis |
| Q64256540 | The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis |
Search more.